Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Femasys Inc (NQ: FEMY )

1.260 -0.070 (-5.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,204,058
Open 1.350
Bid (Size) 1.240 (4)
Ask (Size) 1.270 (1)
Prev. Close 1.330
Today's Range 1.230 - 1.360
52wk Range 0.7340 - 2.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth control 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
Boston IVF to begin providing FemaSeed as an infertility treatment option to expand access for patients across nearly 30 centers nationwide 
From Femasys Inc.
Via GlobeNewswire

Performance

YTD
+24.75%
+24.75%
1 Month
+13.00%
+13.00%
3 Month
+26.00%
+26.00%
6 Month
-6.67%
-6.67%
1 Year
-9.35%
-9.35%

More News

Read More
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
From Femasys Inc.
Via GlobeNewswire
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From Femasys Inc.
Via GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Infertility Clinic Customers from Coast to Coast
From Femasys Inc.
Via GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
From Femasys Inc.
Via GlobeNewswire
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Femasys Inc.
Via GlobeNewswire
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
From Femasys Inc.
Via GlobeNewswire
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event
Via ACCESSWIRE
FEMY Stock Earnings: Femasys Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
From Femasys Inc.
Via GlobeNewswire
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Via Benzinga
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
From Femasys Inc.
Via GlobeNewswire
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.